ethenzamide profile

ethenzamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3282
CHEMBL ID	1483877
CHEBI ID	31564
SCHEMBL ID	25624
MeSH ID	M0070963

Synonym
ethenzamide [inn:ban:jan]
ethenzamidum
4-10-00-00175 (beilstein handbook reference)
l929zck4bf ,
etenzamida
unii-l929zck4bf
lucamide
ethenzamid
etosalicyl
eusal
ethosalicyl
etenzamide
938-73-8
2-ethoxybenzamide
etamide
etosalicil
wln: zvr bo2
katagrippe
nsc-28787
benzamide, o-ethoxy-
etocil
nsc28787
ethbenzamide
protopyrin
benzamide, 2-ethoxy-
pirosolvina
o-ethoxybenzamide
ethenzamide
trancalgyl
inchi=1/c9h11no2/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6h,2h2,1h3,(h2,10,11
STK105005
NCGC00091616-01
2-eethoxybenzamide
nsc 28787
etenzamida [inn-spanish]
brn 2208582
h.p. 209
einecs 213-346-4
anovigam
ethenzamidum [inn-latin]
ccris 9124
etenzamide [dcit]
2-ethoxybenzamide, 97%
ethenzamide (jp17/inn)
ethenzamide (tn)
D01466
AC-11991
smr001307304
MLS002302987
E0222
2-ethoxybenzoylamide
AKOS003280312
A844727
NCGC00091616-02
j3.352i ,
CHEMBL1483877
HMS3039J16
tox21_200025
NCGC00257579-01
dtxsid4020581 ,
dtxcid40581
cas-938-73-8
tox21_111156
S4524
FT-0612206
CCG-213844
SCHEMBL25624
tox21_111156_1
NCGC00091616-03
ethanzamide
KS-5320
orthoethoxybenzamide
ethenzamide [mi]
ethenzamide [who-dd]
ethenzamide [inn]
ethenzamide [jan]
ethenzamide [mart.]
CS-4916
Q-201075
HY-B1428
AB01010349_03
mfcd00007977
SR-01000877236-2
sr-01000877236
CHEBI:31564
ethenzamide 1.0 mg/ml in methanol
Z54953371
Q553324
DB13544
D70657
ethenzamide 100 microg/ml in acetonitrile
EN300-6492973
SY015492

Class	Description
organic molecular entity	Any molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	26.8325	3.1890	29.8841	59.4836	AID1224846
GLI family zinc finger 3	Homo sapiens (human)	Potency	10.4579	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	24.3286	0.0002	21.2231	8,912.5098	AID1259247; AID588516
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	36.8871	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	26.6032	0.0004	17.9460	75.1148	AID1346795
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.2391	0.0002	14.3764	60.0339	AID720691
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	29.4239	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	28.4695	0.0008	17.5051	59.3239	AID1159527; AID1159531
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	0.6682	0.3758	27.4851	61.6524	AID743220
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	61.7278	0.0002	29.3054	16,493.5996	AID743069
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	33.4889	0.0010	24.5048	61.6448	AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	23.8656	0.0237	23.2282	63.5986	AID743222; AID743241
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	47.8020	0.0007	23.0674	1,258.9301	AID743085; AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	30.1065	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	21.0461	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	59.6437	0.0391	47.5451	146.8240	AID1224845; AID1224896
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	1.2589	0.0100	39.5371	1,122.0200	AID588545
heat shock protein beta-1	Homo sapiens (human)	Potency	14.9589	0.0420	27.3789	61.6448	AID743210; AID743228
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	31.6228	0.0200	10.7869	31.6228	AID912
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	8.9125	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay ID	Title	Year	Journal	Article
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID603953	In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	20 (23.81)	18.7374
1990's	12 (14.29)	18.2507
2000's	17 (20.24)	29.6817
2010's	22 (26.19)	24.3611
2020's	13 (15.48)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.16%)	6.00%
Case Studies	7 (8.14%)	4.05%
Observational	0 (0.00%)	0.25%
Other	78 (90.70%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Ache	low	1
Acidosis, Renal Tubular Type IV	low	1
Body Weight	low	1
Cancer of Stomach	low	1
Cancer of the Stomach	low	1
Catarrh	low	1
Chemical Dependence	low	1
Cold, Common	low	1
Common Cold	low	1
Congenital Zika Syndrome	low	1
Congenital Zika Virus Infection	low	1
Coryza, Acute	low	1
Dermatitis Medicamentosa	low	3
Dermatitis, Adverse Drug Reaction	low	3
Disease Models, Animal	low	1
Drug Abuse	low	1
Drug Addiction	low	1
Drug Dependence	low	1
Drug Eruptions	low	3
Drug Habituation	low	1
Drug Overdose	low	1
Drug Use Disorders	low	1
Experimental Hepatoma	low	2
Experimental Hepatomas	low	2
Experimental Liver Neoplasms	low	2
Fever, Zika	low	1
Gastric Cancer	low	1
Gastric Cancer, Familial Diffuse	low	1
Gastric Neoplasms	low	1
Gastric Ulcer	low	1
Hepatoma, Experimental	low	2
Hepatoma, Morris	low	2
Hepatoma, Novikoff	low	2
Hepatomas, Experimental	low	2
Hypoaldosteronism	low	1
Hypoaldosteronism, Hyporeninemic	low	1
Hyporeninemic Hypoaldosteronism	low	1
Inflammation	low	1
Innate Inflammatory Response	low	1
Liver Neoplasms, Experimental	low	2
Maculopapular Drug Eruption	low	3
Maculopapular Exanthem	low	3
Malignant Melanoma	low	1
Melanoma	low	1
Morbilliform Drug Reaction	low	3
Morbilliform Exanthem	low	3
Muscle Contraction	low	1
Neoplasms, Experimental Liver	low	2
Neoplasms, Gastric	low	1
Neoplasms, Stomach	low	1
Organic Mental Disorders, Substance-Induced	low	1
Pain, Burning	low	1
Pain, Crushing	low	1
Pain, Migratory	low	1
Pain, Radiating	low	1
Pain, Splitting	low	1
Prescription Drug Abuse	low	1
Renal Tubular Acidosis, Type IV	low	1
Rheumatic Diseases	low	2
Rheumatism	low	2
Shock, Cardiogenic	low	1
Stomach Cancer	low	1
Stomach Neoplasms	low	1
Stomach Ulcer	low	1
Substance Abuse	low	1
Substance Addiction	low	1
Substance Dependence	low	1
Substance Use	low	1
Substance Use Disorders	low	1
Substance-Related Disorders	low	1
Suffering, Physical	low	1
Type IV Renal Tubular Acidosis	low	1
Zika Fever	low	1
Zika Virus Disease	low	1
Zika Virus Infection	low	1
ZikV Infection	low	1

Article	Year
Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. Journal of pharmacokinetics and biopharmaceutics, Volume: 10, Issue: 6	1982
In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. Journal of pharmacokinetics and biopharmaceutics, Volume: 10, Issue: 6	1982
[Evaluation of the tissue-to-blood partition coefficient R for physiological pharmacokinetic models]. Zhongguo yao li xue bao = Acta pharmacologica Sinica, Volume: 13, Issue: 4	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46	2019
Effect of particle shape of active pharmaceutical ingredients prepared by fluidized-bed jet-milling on cohesiveness. Journal of pharmaceutical sciences, Volume: 94, Issue: 5	2005
[Application of multi-lines fitting technic for ethenzamide elimination with capacity-limited process in the rabbit plasma]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Volume: 109, Issue: 7	1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

ethenzamide

Description

Cross-References

Synonyms (93)

Drug Classes (1)

Protein Targets (21)

Potency Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (10)

Bioassays (44)

Research

Studies (84)

Study Types

Research Highlights

Pharmacokinetics (5)

Bioavailability (4)

Dosage (4)

Article	Year
Studies on the number of contacts between ibuprofen and ethenzamide using thermal analysis. Chemical & pharmaceutical bulletin, Volume: 48, Issue: 1	2000
Carcinogenicity of o-ethoxybenzamide in (C57BL/6N X C3H/HeN)F1 mice. Journal of the National Cancer Institute, Volume: 76, Issue: 1	1986
[Application of multi-lines fitting technic for ethenzamide elimination with capacity-limited process in the rabbit plasma]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, Volume: 109, Issue: 7	1989
Studies on combination dosing (III). Aspirin and ethenzamide. Japanese journal of pharmacology, Volume: 28, Issue: 6	1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
acetone	[no description available]	medium	2	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
benzene	[no description available]	medium	1	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
carbon monoxide	[no description available]	medium	1	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
salicylic acid	[no description available]	medium	3	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
hydroquinone	[no description available]	medium	1	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
methanol	[no description available]	medium	2	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
nitrous oxide	[no description available]	medium	1	gas molecular entity; nitrogen oxide	analgesic; bacterial metabolite; food packaging gas; food propellant; general anaesthetic; greenhouse gas; inhalation anaesthetic; NMDA receptor antagonist; raising agent; refrigerant; vasodilator agent
1-propanol	[no description available]	medium	1	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
toluene	[no description available]	medium	1	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
phenytoin	[no description available]	medium	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acebutolol	[no description available]	medium	1	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
alprazolam	[no description available]	medium	1	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
theophylline	[no description available]	medium	2	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
atenolol	[no description available]	medium	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
barbital	[no description available]	medium	1	barbiturates	drug allergen
betaxolol	[no description available]	medium	1	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
biperiden	[no description available]	medium	1	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisoprolol	[no description available]	medium	1	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
verapamil	[no description available]	medium	1	aromatic ether; nitrile; polyether; tertiary amino compound
chlorpromazine	[no description available]	medium	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
clomipramine	[no description available]	medium	1	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clotiazepam	[no description available]	medium	1	organic molecular entity
diazepam	[no description available]	medium	2	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
valproic acid	[no description available]	medium	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
enflurane	[no description available]	medium	1	ether; organochlorine compound; organofluorine compound	anaesthetic
ether	[no description available]	medium	1	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
fentanyl	[no description available]	medium	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fluoxetine	[no description available]	medium	1	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
haloperidol	[no description available]	medium	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
halothane	[no description available]	medium	1	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
hexobarbital	[no description available]	medium	1	barbiturates
hydroxyzine	[no description available]	medium	1	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
lidocaine	[no description available]	medium	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine	[no description available]	medium	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
isoflurane	[no description available]	medium	1	organofluorine compound	inhalation anaesthetic
2-propanol	[no description available]	medium	1	secondary alcohol; secondary fatty alcohol	protic solvent
lorazepam	[no description available]	medium	1	benzodiazepine
methoxyflurane	[no description available]	medium	1	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methylphenidate	[no description available]	medium	1	beta-amino acid ester; methyl ester; piperidines
metoprolol	[no description available]	medium	1	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic

ethenzamide

Description

Cross-References

Synonyms (93)

Drug Classes (1)

Protein Targets (21)

Potency Measurements

Biological Processes (18)

Molecular Functions (10)

Ceullar Components (10)

Bioassays (44)

Research

Studies (84)

Study Types

Related Drugs (388)

Related Conditions (77)

Research Highlights

Pharmacokinetics (5)

Bioavailability (4)

Dosage (4)